Timothy Smith, M.D., Ph.D.
This page shows the publications co-authored by Timothy Smith and David Reardon.
Improved outcomes associated with maximal extent of resection for butterfly glioblastoma: insights from institutional and national data. Acta Neurochir (Wien). 2021 07; 163(7):1883-1894.
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2021 02 15; 27(4):1048-1057.
Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis. J Neurosurg. 2019 Oct 25; 1-11.
Survival and prognostic factors in surgically treated brain metastases. J Neurooncol. 2019 Jun; 143(2):359-367.
Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunol Res. 2018 09; 6(9):1039-1045.
Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma. JAMA Oncol. 2020 12 01; 6(12):1972-1974.
Predictors and early survival outcomes of maximal resection in WHO grade II 1p/19q-codeleted oligodendrogliomas. Neuro Oncol. 2020 03 05; 22(3):369-380.
An Online Calculator for the Prediction of Survival in Glioblastoma Patients Using Classical Statistics and Machine Learning. Neurosurgery. 2020 02 01; 86(2):E184-E192.
The Misclassification of Diffuse Gliomas: Rates and Outcomes. Clin Cancer Res. 2019 04 15; 25(8):2656-2663.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.